Thermo Fisher Scientific completes acquisition of PPD
The $17.4-billion deal, CDMO says, will help expand its offerings in the clinical development space
Thermo Fisher Scientific Inc., a contract development and manufacturing organization (CDMO), has completed its acquisition of PPD, Inc., a global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion. PPD will now become part of Thermo Fisher's “Laboratory Products and Services” segment.
With the addition of PPD, the CDMO will now be providing services across the clinical development spectrum—from scientific discovery, to assessing safety, efficacy, and health care outcomes, to managing clinical trial logistics, to the development and manufacturing of the drug product.
"We are very excited to officially welcome our PPD colleagues to Thermo Fisher Scientific," notes Marc N. Casper, chairman, president and CEO of Thermo Fisher Scientific. "Expanding our value proposition for our biotech and pharmaceutical customers with the addition of PPD's leading clinical research services advances our work in bringing life-changing therapies to market, benefitting patients around the world."
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
